Metabolic Efficiency Semaglutide in Modern Research Semaglutide is part of a growing class of GLP-1 receptor agonists, which are revolutionizing how obesity and metabolic diseases are studied
Read the full article: To view or add a comment, sign in Great to see Truveta Research featured in Reuters, highlighting the rapid rise in estrogen patch use and resulting supply challenges
Related Stories GLP-1 weight-loss drugs may also reduce binge eating Semaglutide fuels rapid growth in US GLP-1RA use as payments rise Study links GLP-1 treatment to fewer alcohol drinking days In comparison to composite control, GLP-1RA use exhibited a decreased risk of 34 outcomes, including pneumonia, respiratory failure, alcohol use disorders, COPD, and suicidal ideation, and an increased risk of 17 outcomes, including abdominal pain, GERD, nephrolithiasis, and sleep disturbances
It can also lower the chance of a heart attack and other heart problems by keeping the heart and body working well
Toxicol Lett 75, 17783
